Grant: Master's Award: Canada Graduate Scholarships
University of Toronto
$17,500.00
Highly Activated Cancer Associated Fibroblasts Enhance Pancreatic Ductal Adenocarcinoma Progression
FY 2013-14
Summary
Project summary for lay audience
Cancer associated fibroblasts (CAFs) are very plentiful in the microenvironment of pancreatic cancer, an aggressive cancer that has a 5-year survival rate of less than 5%. While CAFs are benign cells, they are closely located next to malignant pancreatic cancer. There is evidence that CAFs can increase pancreatic cancer progression and resistance to chemotherapy. CAFs are different from the inactive fibroblasts that are normally present. Growth factors released by the pancreatic cancer can activate nearby fibroblasts to turn them into CAFs. These activated CAFs produce extra amounts of contractile proteins such as smooth muscle actin. They will also grow rapidly and produce a firm fibrotic environment around pancreatic cancer cells.
There is variation in the level of CAF activation. From our group’s work on lung cancer, we discovered that CAFs with higher contractility increased cancer progression. These highly contractile CAFs also tended to grow faster and their tumours had more firm fibrous tissue. Lastly, activated CAFs produce and secrete proteins such as collagens and enzymes like matrix metalloproteinases that remodel their environment. Our study aims to examine the range of CAF activation based on these aforementioned qualities and their effects on pancreatic cancer progression. We hypothesize that CAFs of higher activity will better promote pancreatic cancer growth and metastasis. The discovery of important characteristics and pathways in fibroblast activation can influence the developmental direction of treatments that target the pancreatic cancer microenvironment. My aims are as follows:
Aim 1: Establish cultured CAFs from 20 human pancreatic cancer samples.
Human pancreatic cancer specimens will be partially digested with enzymes and grown on tissue culture plates to isolate fibroblasts. I will confirm that the grown cells are fibroblasts using immunofluoresence for several markers - keratins, CD31, CD45, CD90, SMA, vimentin, and PDGFR-í (the last four are present in fibroblasts).
Aim 2: Characterize activity of CAFs.
I will look at patient microscope slides to see how much firm fibrous tissue is present in each tumour. I will use special stains to assess how much collagen the CAFs are secreting into their surroundings. I will assess the contractility, growth rates, and enzymatic activity of the CAFs. Using this data, I will classify CAFs as either high activity or low activity. I will then use microarray technology to examine differences in how genes are expressed between these two groups. The findings from microarray will then be confirmed using other methods such as quantitative polymerase chain reaction, western blotting, and immunohistochemistry.
Aim 3: Assess ability of CAFs of different activity to influence tumour progression
The CAFs will be grown on a culture plate with pancreatic cancer cells to see if CAFs of higher activation tend to create larger tumours in culture. I will check to see if CAFs can influence the rate that cancer cells migrate using a transwell assay. I will also implant pancreatic cancer cells and CAFs into mice to test the effects of CAF activation on tumour growth and metastatic spread.
With these experiments, I hope to confirm our unique hypothesis that the ability of CAFs to promote pancreatic cancer progression depends on its level of activity. This would support the need to develop therapies that target the molecular pathways that activate CAFs. It would highlight the importance of disrupting the harmful cancer-CAF interaction to achieve more effect treatments for pancreatic cancer.
Department
Program
Master's Award: Canada Graduate Scholarships
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
311949
Name
Wang Tao
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Highly Activated Cancer Associated Fibroblasts Enhance Pancreatic Ductal Adenocarcinoma Progression
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Cancer Associated Fibroblasts; Flow Cytometry; Immunohistochemistry; Metastasis; Microarray; Orthotopic Mouse Model; Pancreatic Cancer; Tissue Culture; Tumour Invasion; Tumour Microenvironment
Abstract
Project summary for lay audience
Cancer associated fibroblasts (CAFs) are very plentiful in the microenvironment of pancreatic cancer, an aggressive cancer that has a 5-year survival rate of less than 5%. While CAFs are benign cells, they are closely located next to malignant pancreatic cancer. There is evidence that CAFs can increase pancreatic cancer progression and resistance to chemotherapy. CAFs are different from the inactive fibroblasts that are normally present. Growth factors released by the pancreatic cancer can activate nearby fibroblasts to turn them into CAFs. These activated CAFs produce extra amounts of contractile proteins such as smooth muscle actin. They will also grow rapidly and produce a firm fibrotic environment around pancreatic cancer cells.
There is variation in the level of CAF activation. From our group’s work on lung cancer, we discovered that CAFs with higher contractility increased cancer progression. These highly contractile CAFs also tended to grow faster and their tumours had more firm fibrous tissue. Lastly, activated CAFs produce and secrete proteins such as collagens and enzymes like matrix metalloproteinases that remodel their environment. Our study aims to examine the range of CAF activation based on these aforementioned qualities and their effects on pancreatic cancer progression. We hypothesize that CAFs of higher activity will better promote pancreatic cancer growth and metastasis. The discovery of important characteristics and pathways in fibroblast activation can influence the developmental direction of treatments that target the pancreatic cancer microenvironment. My aims are as follows:
Aim 1: Establish cultured CAFs from 20 human pancreatic cancer samples.
Human pancreatic cancer specimens will be partially digested with enzymes and grown on tissue culture plates to isolate fibroblasts. I will confirm that the grown cells are fibroblasts using immunofluoresence for several markers - keratins, CD31, CD45, CD90, SMA, vimentin, and PDGFR-í (the last four are present in fibroblasts).
Aim 2: Characterize activity of CAFs.
I will look at patient microscope slides to see how much firm fibrous tissue is present in each tumour. I will use special stains to assess how much collagen the CAFs are secreting into their surroundings. I will assess the contractility, growth rates, and enzymatic activity of the CAFs. Using this data, I will classify CAFs as either high activity or low activity. I will then use microarray technology to examine differences in how genes are expressed between these two groups. The findings from microarray will then be confirmed using other methods such as quantitative polymerase chain reaction, western blotting, and immunohistochemistry.
Aim 3: Assess ability of CAFs of different activity to influence tumour progression
The CAFs will be grown on a culture plate with pancreatic cancer cells to see if CAFs of higher activation tend to create larger tumours in culture. I will check to see if CAFs can influence the rate that cancer cells migrate using a transwell assay. I will also implant pancreatic cancer cells and CAFs into mice to test the effects of CAF activation on tumour growth and metastatic spread.
With these experiments, I hope to confirm our unique hypothesis that the ability of CAFs to promote pancreatic cancer progression depends on its level of activity. This would support the need to develop therapies that target the molecular pathways that activate CAFs. It would highlight the importance of disrupting the harmful cancer-CAF interaction to achieve more effect treatments for pancreatic cancer.
Competitiondate
201312
Approvedterm2
1 yr 0 mth
Pinamesdelim
Wang, Tao
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~